Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Xenoport, Inc. ("Xenoport" or the "Company") (NASDAQ:XNPT) for potential breaches of fiduciary duties in connection with the sale of the Company to Arbor Pharmaceuticals, LLC for approximately $467 million. The Company's stockholders will only receive $7.03 in cash for each share of Company common stock they own. However, this consideration is below at least one analyst's price target of $10.00 per share and Xenoport's 52-week high of $7.86 per share. Click here for more information: www.faruqilaw.com/XNPT . There is no cost or obligation to you. The investigation focuses on whether Xenoport's Board of Directors breached their fiduciary duties to the Company's stockholders by failing to conduct a fair sales process and whether and by how much this proposed transaction undervalues the Company to the detriment of Xenoport's shareholders. Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action litigation. The firm is focused on providing exemplary legal services in complex litigation in the areas of securities, shareholder, antitrust and consumer litigation, throughout all phases of litigation. The firm has an experienced trial team which has achieved significant victories on behalf of the firm's clients. To keep track of the latest securities litigation news, follow us on Twitter at www.twitter.com/MergerActivity or on Facebook at www.facebook.com/FaruqiLaw. If you own common stock in Xenoport and wish to obtain additional information and protect your investments free of charge, please visit us at www.faruqilaw.com/XNPT or contact Juan Monteverde, Esq. either via e-mail at firstname.lastname@example.org or by telephone at (877) 247-4292 or (212) 983-9330. Attorney Advertising. (C) 2016 Faruqi & Faruqi, LLP. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We are happy to discuss your particular case.